Results 31 to 40 of about 33,569 (238)

No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers

Breast Cancer Research and Treatment, 2007
Q2 ; Q1 ; Editorial ; 155-156 ; To the editorAbout 5% of breast cancers and 10% of ovariancancers are a result of germ line mutations in theBRCA1(MIM 113705) andBRCA2(MIM 600185)genes [1,2].
Muhammad U, Rashid, Diana, Torres, Anbreen, Zaidi, Farah, Rasheed, Faisal, Sultan, Abdul R, Shakoori, Asim, Amin, Ute, Hamann   +7 more
openaire   +3 more sources

BRCA germline mutation test for all woman with ovarian cancer?

BMC Cancer, 2019
Background Delivering widespread BRCA testing to patients with ovarian cancer has been suggested by several scientists, recommended by professional societies and solicited by patients organizations.
A. V. Paradiso, M. Digennaro, M. Patruno, S. De Summa, S. Tommasi, I. Berindan-Neagoe   +5 more
doaj   +1 more source

Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? [PDF]

PLoS ONE, 2018
Hereditary breast and ovarian cancer syndrome (HBOC) is most frequently caused by mutations in BRCA1 or BRCA2 (in short, BRCA) genes. The incidence of hereditary breast and ovarian cancer in relatives of BRCA mutation carriers who test negative for the ...
Rachel Mitchell, Lela Buckingham, Melody Cobleigh, Jacob Rotmensch, Kelly Burgess, Lydia Usha   +5 more
doaj   +1 more source

Management of the asymptomatic BRCA mutation carrier

The Application of Clinical Genetics, 2010
Current management of an asymptomatic BRCA mutation carrier includes early initiation and intensive cancer screening in combination with risk reduction strategies. The primary objectives of these interventions are earlier detection and cancer prevention to increase quality of life and prolonged survival.
Teller,Paige, Kramer,Rita
openaire   +5 more sources

Evaluation of BRCAPRO risk assessment model in patients with ductal carcinoma in situ who underwent clinical BRCA genetic testing.

Frontiers in Genetics, 2016
The authors retrospectively aimed to determine which of the following 3 scenarios, related to DCIS entry into BRCAPRO, predicted BRCA mutation status more accurately: 1) DCIS as an invasive breast cancer (IBC) entered using the actual age of diagnosis, 2)
Nisreen eElsayegh, Angelica M. Gutierrez Barrera, Kimberly I. Muse, Heather eLin, Henry M Kuerer, Monica eHelm, Jennifer K. Litton, Banu K. Arun, Banu K. Arun   +8 more
doaj   +1 more source

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer

Breast, 2022
Background: HER2-positive breast cancers are rare amongst BRCA mutation carriers. No data exist regarding clinicopathological characteristics and prognosis of this subgroup of patients.
A. Viansone, B. Pellegrino, C. Omarini, M. Pistelli, D. Boggiani, A. Sikokis, V. Uliana, D. Zanoni, C. Tommasi, B. Bortesi, F. Bonatti, F. Piacentini, L. Cortesi, R. Camisa, P. Sgargi, M. Michiara, A. Musolino   +16 more
doaj   +1 more source

BRCA Mutations and Breast Cancer Prevention [PDF]

Cancers, 2018
Women who inherit a deleterious BRCA1 or BRCA2 mutation face substantially increased risks of developing breast cancer, which is estimated at 70%. Although annual screening with magnetic resonance imaging (MRI) and mammography promotes the earlier detection of the disease, the gold standard for the primary prevention of breast cancer remains bilateral ...
openaire   +2 more sources

Expert consensus on population-based BRCA germline mutation screening in China (2024 edition) [PDF]

Zhongguo aizheng zazhi
Germline mutations in BRCA genes (including BRCA1/2) are the major risk factors for hereditary tumors including breast and ovarian cancer. Population based BRCA gene screening, particularly in high-risk individuals with a family history of cancer, can ...
China Anti-Cancer Association Tumor Biomarker Professional Committee, Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee
doaj   +1 more source

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study

Frontiers in Oncology, 2022
ObjectiveTo study the correlation between BRCA mutation status and the risk of adverse reactions in patients with ovarian cancer.MethodA real-world study was conducted at the largest gynecological oncology center in western China, the West China Second ...
Kemin Li, Kemin Li, Jing Zeng, Jing Zeng, Mengpei Zhang, Mengpei Zhang, Rutie Yin, Rutie Yin, Zhengyu Li, Zhengyu Li   +9 more
doaj   +1 more source

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients

Gynecologic Oncology Reports, 2020
To evaluate BRCA1/2 immunohistochemistry (IHC) as a screening test for germline BRCA1/2 in epithelial ovarian cancer (EOC), tumor tissue from 105 EOC patients who had germline BRCA mutations, including 9 BRCA1 mutations, 6 BRCA2 mutations and 90 no BRCA mutations, were studied. Paraffin-embedded tissue blocks were stained for BRCA1 and BRCA2.
Tarinee Manchana, Patou Tantbirojn, Natkrita Pohthipornthawat   +2 more
openaire   +3 more sources